Celerion Selected by the Foundation for the National Institu...
Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consorti...
News
Celerion and Korean Drug Development Fund Form Collaboration...
Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Rese...
News
Celerion Opens Operations in South Korea at Seoul National U...
Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center...
News
Celerion Celebrates 80 Years of Conducting Business at Globa...
Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska (Lin...
News
Celerion Appoints John Horkulak as Executive Director, Euras...
Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations (Lincoln, NE; Dec 5,...
News
Celerion Appoints Clayton Dehn as Executive Director, Metabo...
Celerion Appoints Clayton Dehn as Executive Director, Metabolic Diseases (Lincoln, NE; Nov 5, 2013) ...
News
Celerion Expands Belfast Facility with Containment Room to E...
Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies...
News
Celerion appoints Dr. Bruce Morimoto as Executive Director,...
Celerion appoints Dr. Bruce Morimoto as Executive Director, Applied Translational Medicine (Lincoln,...
News
Types and Features of NDA Enabling
Types and Features of NDA Enabling Studies J. Fred Pritchard, Ph.D. Vice President, Global Drug Deve...